Friday, October 30, 2026

TherapeuticsMD Stock Went Up By Over 27% In The Last 21 Sessions

TherapeuticsMD Stock Went Up By Over 27% In The Last 21 Sessions

(VIANEWS) - Shares of TherapeuticsMD (NASDAQ: TXMD) jumped by a staggering 27.25% in 21 sessions from $3.67 at 2023-04-17, to $4.67 at 11:55 EST on Tuesday, following the last session's downward trend. NASDAQ is rising 0.17% to $12,386.53, following the last session's upward trend.

TherapeuticsMD's last close was $4.39, 62.45% below its 52-week high of $11.69.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $0.11.

PE Ratio

TherapeuticsMD has a trailing twelve months price to earnings ratio of 42.45. Meaning, the purchaser of the share is investing $42.45 for every dollar of annual earnings.

Volatility

TherapeuticsMD's last week, last month's, and last quarter's current intraday variation average was 4.63%, 1.06%, and 3.04%.

TherapeuticsMD's highest amplitude of average volatility was 4.63% (last week), 3.11% (last month), and 3.04% (last quarter).

Sales Growth

TherapeuticsMD's sales growth is negative 91.2% for the present quarter and negative 93.7% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TherapeuticsMD's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for TherapeuticsMD is 13091 which is 68.6% below its average volume of 40045.

More news about TherapeuticsMD (TXMD).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com